Conference Call

9M 2022 Results

Joachim Kreuzburg, Rainer Lehmann

Sartorius | Sartorius Stedim Biotech | October 19, 2022

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results substantially diverging from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

2

Highlights

  • Double-digitgrowth of sales revenues and earnings in both divisions
  • Healthy profitability based on positive scale effects, diluted by higher cost base and FX-related headwinds
  • Fundamentally strong market impacted by rapid normalization of demand in bioprocessing domain
  • Outlook for 2022 specified for sales growth with unchanged profitability
  • Uncertainties remain high due to global geopolitical and economic situation

3

Acquisition of Albumedix further strengthens the portfolio for advanced therapies

Nottingham, UK

>100 employees

GMP manufacturing and R&D laboratories

  • 33m revenue expected for 2022, significant double-digit EBITDA margin

Recombinant albumin

Strategic rationale

  • Leader in the field of recombinant albumin, a critical component in the manufacture and formulation of innovative biopharmaceuticals
  • Strengthens Sartorius' position as a relevant supplier of animal- component free media and critical ancillary materials
  • Complements cell culture media business particularly for advanced therapy

Acquisition terms

  • Purchase price of ~£415m in cash for 100% stake
  • Acquisition closed as of September 30, 2022

4

Agenda

Sartorius Group

9M 2022 results | FY 2022 guidance

Sartorius Stedim Biotech Group

9M 2022 results | FY 2022 guidance

Questions & Answers

5

Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sartorius AG published this content on 19 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2022 12:32:56 UTC.